BridgeBio Pharma Inc’s filing revealed that its Chief Executive Officer Kumar Neil unloaded Company’s shares for reported $2.24 million on Dec 15 ’25. In the deal valued at $74.64 per share,30,011 shares were sold. As a result of this transaction, Kumar Neil now holds 228,776 shares worth roughly $16.93 million.
Then, NEIL KUMAR bought 30,011 shares, generating $2,255,327 in total proceeds.
Before that, Apuli Maricel sold 2,000 shares. BridgeBio Pharma Inc shares valued at $148,520 were divested by the Chief Accounting Officer at a price of $74.26 per share. As a result of the transaction, Apuli Maricel now holds 130,297 shares, worth roughly $9.64 million.
Morgan Stanley initiated its BridgeBio Pharma Inc [BBIO] rating to an Overweight in a research note published on January 06, 2026; the price target was $96. A number of analysts have revised their coverage, including Bernstein’s analysts, who began to cover the stock in mid December with a ‘”an Outperform”‘ rating. Truist started covering the stock on July 21, 2025. It rated BBIO as “a Buy”.
Price Performance Review of BBIO
On Tuesday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock jump 0.78% to $73.99. Over the last five days, the stock has lost -2.14%. BridgeBio Pharma Inc shares have risen nearly 162.38% since the year began. Nevertheless, the stocks have fallen -3.27% over the past one year. While a 52-week high of $78.58 was reached on 01/05/26, a 52-week low of $27.86 was recorded on 01/06/26.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 72.02, which if violated will result in even more drops to 70.06. On the upside, there is a resistance level at 75.12. A further resistance level may holdings at 76.26.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-12-15, dropping by -1.9 million shares to a total of 18.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 20.69 million shares. There was a decline of -10.1%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on July 14, 2025 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
